At a glance
ClinicalIndex Comparison RecordN/ACompleted· 66 enrolled
Drug / intervention
BPH 3-item questionnaireother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
To Linguistically and Psychometrically Validate the Hong Kong Chinese Version of the BPH 3-item Questionnaire.
In Brief
An observational study evaluating BPH 3-item questionnaire for Benign Prostatic Hyperplasia (BPH). Completed, enrolled 66 participants across 2 sites.
Detailed Summary
This study is to linguistically and psychometrically validate the translated and culturally adapted Hong Kong Chinese version of the BPH 3-item questionnaire.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBenign Prostatic Hyperplasia (BPH)
CountriesHong Kong
Collaborators--
Timeline
N/ACompletedFinished
202420252026
Enrollment StartFeb 2023
First PostedMar 2023
Primary CompletionJul 2024
Study CompletionOct 2024
TodayJul 2026
First PostedMar 27, 2023
Enrollment StartFeb 27, 2023
Primary CompletionJul 31, 2024
Study CompletionOct 30, 2024
TodayJul 1, 2026
Enrollment to primary: 1.4 yearsPosted 3.3 years ago
Interventions
BPH 3-item questionnaireother
BPH 3-item questionnaire. The questionnaire consists of only three items. A raw score ranging from 0 to 5 is assigned to each of the items, giving a final total score varying from 0 (no symptom) to 15 (very symptomatic).